Drug Development Technology Leader ArisGlobal Completes Acquisition of Amplexor Life Sciences

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Sino BioPharm to Acquire LaNova Medicines for $950.9 M Deal

LaNova Medicines, which happens to be a cancer drugmaker...

Rheumatoid Arthritis Treatment with Genetic Link Adds Hope

Researchers at the University of Edinburgh have gone on...

Sleep Lean Reviews – Is It Effective for Weight Loss?

Sleep Lean is a dietary supplement formulated for people...

CDSCO Moves to Online Submission for CGTP Trial Applications

As part of its continued efforts to streamline operations...

ArisGlobal, the leading provider of life sciences software designed to automate core drug development functions with its end-to-end technology platform LifeSphere®, announces the completion of its acquisition of Amplexor Life Sciences. This deal will deliver the most intelligent, connected, and comprehensive regulatory platform available, bringing increased efficiency for life sciences organizations as they bring new therapies to market.

A key development is the introduction of LifeSphere Quality Management, marking ArisGlobal’s entry into the continuous quality improvement and risk management aspects of drug development.

LifeSphere Quality represents an expansion of ArisGlobal’s interconnected drug development platform that spans the pharmaceutical product lifecycle including Clinical, Regulatory, Medical Affairs and Safety. Robust quality management system (QMS) capabilities, including automated workflows and analytics, are now available to support customers’ global regulatory compliance needs.

The acquisition also rounds out the end-to-end LifeSphere Regulatory platform with the addition of a labeling management solution and accelerates the Regulatory product roadmap through the integration of enhanced global submission publishing capabilities.

ArisGlobal’s intent to purchase was previously announced in late February 2023, and brings two new office locations in Croatia and Slovenia into ArisGlobal’s geographic footprint.

Latest stories

Related stories

Sino BioPharm to Acquire LaNova Medicines for $950.9 M Deal

LaNova Medicines, which happens to be a cancer drugmaker...

Rheumatoid Arthritis Treatment with Genetic Link Adds Hope

Researchers at the University of Edinburgh have gone on...

Sleep Lean Reviews – Is It Effective for Weight Loss?

Sleep Lean is a dietary supplement formulated for people...

CDSCO Moves to Online Submission for CGTP Trial Applications

As part of its continued efforts to streamline operations...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back